Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain

Infection and Immunity

Volumn 64, Issue 12, 1996, Pages 5219-5224

  Nardelli Haefliger, Denise ^a   Kraehenbuhl, Jean Pierre ^b   Iii, Roy Curtiss ^c   Schödel, Florian ^d   Potts, Alexandra ^a   Kelly, Sandra ^c   De Grandi, Pierre ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; HEPATITIS B CORE ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIVE VACCINE; RECOMBINANT VACCINE; SECRETORY IMMUNOGLOBULIN; TYPHOID VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTAL DRUG ADMINISTRATION; SALMONELLA TYPHI; SEROCONVERSION;

EID: 0029803846     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.64.12.5219-5224.1996     Document Type: Article

References (51)

1. Bao, J. X., and J. D. Clements. 1991. Prior immunologie experience potentiates the subsequent antibody response when Salmonella strains are used us vaccine curriers. Infect. Immun. 59:3841-3845.
2. Bartholomeusz, R. C. A., B. D. Forrest, J. T. LaBrooy, P. L. Ey, D. Pyle, and D. J. C. Shearman. 1990. The serum polymeric IgA antibody response to typhoid Vaccination: its relationship to the intestinal IgA response. Immunology 69:190-194.
3. Bartholomeusz, R. C. A., J. T. LaBrooy, M. Johnson, D. J. C. Shearman, and D. Rowley. 1986. Gut immunity to typhoid: the immune response to a live oral typhoid vaccine Ty21a. J. Gastroenterol. Hepatol. l:61-67.
4. Beltantl, J. A., B. J. Zeugs, S. Vetro, Y. H. Pung, S. Luccloll. M. J. Malavaslc. A. M. Hooke, T. R. Ubertini, R. Vanni, and L. Nenclonl. 1993. Studies of safety, infectivity and immunogenicity of a new temperature-sensitive (Is) 51-1 strain of Salmonella typhi as a new live oral typhoid fever vaccine candidate. Vaccine 11:587-590.
5. Curtiss, R., J. E. Galan, K. Nakayama, and S. M. Kelly. 1990. Stabilization of recombinant avirulent vaccine strains in vivo. Res. Microbiol. 141:797-806.
6. Curtiss, R., J, O. Hassan, J. Herr, S. M. Kelly, M. Levine, G. G. Mahalras, D. Milich, D. Peterson, F. Schödel, J. Srinivasan, C. Tacket, S. A. Tinge, and R. Wright. 1994. Nonrecombinant and recombinant avirulent Salmonella vaccines, p. 340-351. In G. P. Talwar et al. (ed.), Recombinant and synthetic vaccines. Narosa Publishing House, New Delhi, India.
7. Curtiss, R., III, and S. M. Kelly. 1987. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect. Immun. 55:3035-3043.
8. Curtiss, R., S. M. Kelly, S. A. Tinge, C. O. Tacket, M. M. Levine, J. Srinivasan, and M. Koopman. 1994. Recombinant Salmonella vectors in vaccine development. Dev. Biol. Stand. 82:23-33.
9. Curtiss, R., K. Nakayama, and S. M. Kelly. 1989. Recombinant avirulent Salmonella vaccine strains with stable maintenance and high level expression of cloned genes in vivo. Immunol. Invest. 18:583-596.
10. 9a. Curtiss, R., III. Unpublished data.
11. Czerkinsky, C., A.-M. Svennerholm, M. Quiding, R. Jonsson, and J. Holmgren. 1991. Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect. Immun. 59:996-1001.
12. Delos, S., M.T. Villar, P. Hu, and D. L. Peterson. 1991. Cloning, expression, isolation and characterization of the pre-S domains of hepatitis D surface antigen, devoid of the S protein. Biochem. J. 276(Suppl.):411-416.
13. Ferguson, A., and J. Sallam. 1992. Mucosal immunity to oral vaccines, Lancet 339:8786. (Letter: comment.)
14. Ferreccio, C., M. M. Levine, H. Rodriguez, and R. Contreras. 1989. Comparative efficacy of two. three, or four doses of TY2l a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic urea. J. Infect. Dis. 159:766-769.
15. Forrest, B. C. 1992. Indirect measurement of intestinal immune responses to an orally administered attenuated bacterial vaccine. Infect. Immun. 10:2023-2029.
16. Forrest, B. C., J. T. LaBrooy, L. Beyer, C. E. Dearlove, and D. J. C. Shearman. 1991.The human humoral immune response to Salmonella typhi Ty21 a. J. Infect. Dis. 163:336-345.
17. Forrest, B. D. 1992. Impairment of immunogenicity of Salmonella typhi Ty2hi due to preexisting cross-reacting intestinal antibodies. J. Infect. Dis. 166:210-212.
18. Forrest, B. D., J. T. LaBrooy, C. D. Dearlove, and D. J. C. Shearman. 1992. Effect of parenteral immunization on the intestinal immune response to Salmonella typhi Ty21a. Infect. Immun. 60:465-471.
19. Forrest, B. D., J. T. LaBrooy, P. Robinson, C. E. Dearlove, and D. J. C. Shearman. 1991. Specific immune response in the human respiratory tract following oral immunization with live typhoid vaccine. Infect. Immun. 59: 1206-1209.
20. Forrest, B, D., D. J. C, Shearman, and J. T. LaBrooy. 1990. Specific immune response in humans following rectal delivery of live typhoid vaccine. Vaccine 8:209-212.
21. Galaacute;n, J. E., K. Nakayama, and K. Curtiss. 1990. Cloning and characterization of the asd gene of Salmonella tphimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene 94:29-35.
22. Gurmanier, R., and E. Fürer. 1975. Isolation and characterization of gal E mutant Ty 21a of Salmonella typhi. A candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 131:553-558.
23. Hahn, Z. M., B. Carlson, F. Jalil, L. Mellander, R. Germanlor, and L. A. Hanson. 1989. The influence on the secretory IgA antibody levels in banting women of oral typhoid and parenteral cholera vaccines given alone or in combination, Scand. J. Infect. Dis. 21:421-426.
24. Haneberg, B., and D. Aarskog. 1975. Human faecal immunoglobulins in healthy infants and children, and in some with diseases affecting the intestinal tract or the immune system. Clin. Exp. Immunol. 22:210-222.
25. Haneherg, B., D. Kendall, H. M. Amerongen, F. M. Apter, J.-P. Krachenbuhl, and M. R. Neutra. 1994. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosul surfaces. Infect. Immun. 62:15-23.
26. Hone, D. M., C. Tacket, A. M. Harris, B. Kay, G. Losonsky, and M. M. Levine. 1992. revaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J. Clin. Invest. 90:412-420.
27. Hopkins, S., J.-P. Kruehenbuhl, F. Schödel, A. Poterson, D. Peterson, P, De Grandi, and D. Nardelli-Haefliger. 1995. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect. Immun. 63:3279-3286.
28. Jiang, Z. D., A. C. Nelson, J. J. Mathewson, C. D. Ericsson, and H. L. DuPont. 1991. Intestinal secretory immune response to infection with Aero- monus species and Plesiomonas shigelloides among students from the United States in Mexico. J. Infect. Dis. 164:979-982.
29. Kantele, A., and P. H. Makelu. 1991. Different profiles of the human immune response to primary and secondary immunization with an oral Salmonella typhi Ty21a vaccine. Vaccine 9:423-427.
30. Kelly, S. M., B. A. Bosecker, and K. Curtiss III. 1992. Characterization and protective properties of attenuated mutants of Salmonella choleraesuis. Infect. Immun. 60:4881-4890.
31. Lehner, T., C. Panagiotidi, L. A. Bergmeier, T. Ping, R. Brookes, and S. E. Adams. 1992. A comparison of the immune response following oral, vaginal, or rectal route of immunization with SIV antigens in nonhunian primatex. Vaccine Res. 1:319-330.
32. Levine, M. M., D. Herrington, J. R. Murphy, J. G. Morris, G. Losonsky, B. Tall, A. Lindberg, S. Stevenson, S. Bagar, M. F. Edwards, and B. A. D. Stocker. 1987. Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in man. J. Clin. Invest. 79:888-902.
33. McDermott, M., and J. Bienenstock. 1979. Evidence for a common mucosal immunologic system, I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J. Immunol. 122:1892-1898.
34. Ogra, P. L., and S. S. Ogra. 1973. Local antibody response lo poliovaccine in the human female genital tract. J. Immunol. 110:1307-1311.
35. Roberts, M., S. N. Chalfield, and G. Dougan. 1994. Salmonella as carriers of heterologous antigens, p. 27-58. CRC Press Inc. Boca Raton, Fia.
36. Schödel, F. 1992. Prospects for oral vaccination using recombinant bacteria expressing viral epitopes. Adv. Virus Res. 41:409-446.
37. Schödel, F., S. Kelly, S. Tlnge, S. Hopkins, D. Peterson, D. Milich, and R. Curtiss III. 1996. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety. II. Expression in avirulent Salmonella spp. for mucosal immunmi- tion. p. 15-21. In S. Cohen and A. Shafferman (ed.), Novel strategics in design and production of vaccines. Plenum Press, New York.
38. Schödel, F., S. M, Kelly, D. Peterson, D. Milich, J. Hughes, S. Tinge, R. Wlrtz, and R. Curtiss III. 1994. Development of recombinant Salmonella expressing hybrid hepatitis B virus core particles as candidate oral vaccines. Dev. Biol. Stand. 82.
39. Schödel, F., S. M. Kelly, D. L. Peterson, D. R. Milich, and R. Curtiss III. 1994. Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination. Infect. Immun. 62:1669-1676.
40. Schödel, F., D. R. Milich, and H. Will, 1990. Hepatitis B virus nueleocapsid/ pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination. J. Immunol. 145:4317-4321.
41. Schödel, F., D. K. Milich, and H. Will. 1991. Hybrid hepatitis B virus corepre-S particles expressed in live attenuated Salmonella for oral immunization. Vaccines (Cold Spring Harbor) 1991:319-330.
42. Schödel, F., D. Peterson, J. Hughes, and D. R. Milich. 1993. Hybrid hepatitis B virus core/pre-S panicles: position effects on immunogenicity of heterologous epitopes and expression in avirulent Salmonellae for oral vaccination. Plenum Press, New York.
43. Silva, B. A., C. Gonzalez, G. C. Moral, and F. Cabello. 1987. Genetic characteristics of the Salmonella typhi strain Ty21a vaccine. J. Infect. Dis. 155: 1077-1078.
44. Srinivasan, J., A. Nayak, and R. Curtiss III. 1995. Effect of the route of immunization using recombinant Salmonella an mucosal and humoral im- mune responses. Vaccines (Cold Spring Harbor) 1995:184-195.
45. Srinivasan, J., S. Tinge, R. Wright, J. C. Herr, and R. Curtiss. 1995. Oral immunization with attenuated salmonella expressing human sperm antigen induces antibodies in serum and the reproductive tract. Biol. Reprod. 53: 462-471.
46. Tacket, C. O., B. Forrest, R. Morona, S. R. Altridge, J. LaBrooy, B. D. Tall, M. Reymann, D. Rowley, and M. M. Levine. 1990. Safety. immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect. Immun. 58:1620-1627.
47. Tacket, C. O., D. M. Hone, R. Curtiss III, S. M. Kelly, G. Losonsky, L. Guers, A. M. Harris, R. Edelman, and M. M. Levine. 1942. Comparison of the safety and immunogenicity of ΔaroC ΔaroD and Δcya Δcrp Salmonella typhi strains in adult volunteers. Infect. Immun. 60:536-541.
48. Tacket, C. O., D. M. Hone, G. Losonsky, L. Guers, R. Edelman, and M. M. Levine. 1992. Clinical acceptability and immunogenicity of CVD908 Salmonella typhi vaccine strain. Vaccine 10:443-446.
49. Vos, J. G., J, Buys, J. G. Hanstede, and A. M. Hagenaars. 1979. Comparison of enzyme-linked immunosorbent assay and passive hemagglutination method for quantification of antibodies to lipopulysaccharide and tetanus toxoid in rats. Infect. Immun. 24:798-803.
50. Waldman, R. H., J. M. Cruz, and D. S. Rowe. 1972. Intruvaginul immunization of humans with Candida albicans, J. Immunol. 109:662-664.
51. Wu, H.-Y., and M. Russell. 1993. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect. Immun. 61:314-322.